TCRR News and Press, TCR2 Therapeutics Inc. From 09/13/21

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio we...

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therape...

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted t...

CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Director...

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that their interim update on the Phase 1/2 clinical trial of ga...

New clinical data from gavo-cel Phase 1 trial to be presented at European Society of Medical Oncology (ESMO) Remain on track to identify recommended Phase 2 dose (RP2D) for gavo-cel in 2021 TCR 2 to host virtual R&D Day on October 20, 2021 to highlight emerging pipeline ...

Dr_Microbe/iStock via Getty Images TCR2 Therapeutics (TCRR)  has appointed Peter Olagunju as Chief Technical Officer where he will oversee process development, manufacturing, quality control and technical operations for the Company's TRuC-T cell programs and emerging pipeline. Olagu...

CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid tumors, today announced the appointment of Peter Olagunju as Chief Technical Officer...

TCRR is developing an exciting new TCR-T cell-based therapy that has the potential to deliver improved therapeutic outcomes when compared to CAR-T cell-based therapies. TCRR appears to be undervalued and shows promising upside potential. The company recently released first-quarter...

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate at two upcoming conferences in ...